Nanoparticle-conjugated aptamer targeting hnRNP A2/B1 can recognize multiple tumor cells and inhibit their proliferation.

Abstract

In this study, we further investigated a previously developed aptamer targeting ROS 17/2.8 (rat osteosarcoma) cells. We found that this C6-8 aptamer specifically binds to heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 and that it specifically labeled multiple tumor-cell lines as effectively as hnRNP A2/B1 monoclonal antibodies. When conjugated with fluorescent carbon nanodots (CDots) it could freely enter multiple living tumor cell lines (HepG2, MCF-7, H1299, and HeLa), whose growth it inhibited by targeting hnRNP A2/B1. Similar inhibitory effects were observed when the GFP-HepG2 hepatocarcinoma cells treated with C6-8-conjugated CDots were implanted in nude mice. Our work provides a new aptamer for targeting/labeling multiple tumor cell types, and its nanoparticle conjugates bring further advantages that increase its potential for use in cancer diagnosis and therapy.

• Authors: Hui Li, Lei Guo, Aixue Huang, Hua Xu, Xuemei Liu, Hongmei Ding, Jie Dong, Jie Li, Chaonan Wang, Xueting Su, Xingfeng Ge, Leqiao Sun, Chenjun Bai, Xuelian Shen, Tao Fang, Zhanghua Li, Yong Zhou, Linsheng Zhan, Shaohua Li, Jianwei Xie, Ningsheng Shao
• Journal: Biomaterials (Biomaterials) Vol. 63 Pg. 168-76 (Sep 2015) ISSN: 1878-5905 [Electronic] Netherlands
• PMID: 26107993 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Aptamers, Nucleotide
• Heterogeneous-Nuclear Ribonucleoprotein Group A-B
• Nanoconjugates

Topics

• Animals
• Aptamers, Nucleotide (chemistry, metabolism, pharmacokinetics, pharmacology)
• Base Sequence
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Drug Delivery Systems
• Heterogeneous-Nuclear Ribonucleoprotein Group A-B (metabolism)
• Humans
• Mice, Inbred BALB C
• Mice, Nude
• Nanoconjugates (chemistry)
• Neoplasms (drug therapy, metabolism, pathology)
• Rats